Edwards Lifesciences Corporation Payments to Acquire Debt Securities, Available-for-sale
Edwards Lifesciences Corporation (EW) reported Payments to Acquire Debt Securities, Available-for-sale of $1.20 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- Edwards Lifesciences Corporation payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $558.30M, a 10.57% decline year-over-year.
- Edwards Lifesciences Corporation payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $641.10M, a 1.04% increase year-over-year.
- Edwards Lifesciences Corporation payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $826.60M, a 116.90% increase year-over-year.
- Edwards Lifesciences Corporation payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $1.01B, a 94.66% increase year-over-year.
- Edwards Lifesciences Corporation payments to acquire debt securities, available-for-sale for fiscal 2025 was $3.09B, a 243.57% increase from fiscal 2024.
- Edwards Lifesciences Corporation payments to acquire debt securities, available-for-sale for fiscal 2024 was $899.90M, a 9789.01% increase from fiscal 2023.
- Edwards Lifesciences Corporation payments to acquire debt securities, available-for-sale for fiscal 2023 was $9.10M, a 97.12% decline from fiscal 2022.
- Edwards Lifesciences Corporation payments to acquire debt securities, available-for-sale for fiscal 2022 was $315.80M, a 80.62% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $558.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.20B 10-Q · filed 2026-08-04 | $2.03B derived: sum of 3 quarters · filed 2026-08-04 | $3.03B derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $641.10M 10-Q · filed 2026-05-06 | $1.47B derived: sum of 2 quarters · filed 2026-05-06 | $2.47B derived: sum of 3 quarters · filed 2026-05-06 | $3.10B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $826.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.83B derived: sum of 2 quarters · filed 2026-02-25 | $2.46B derived: sum of 3 quarters · filed 2026-08-04 | $3.09B 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.01B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.63B derived: sum of 2 quarters · filed 2026-08-04 | $2.27B 10-Q · filed 2025-11-05 | $2.65B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $624.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.26B 10-Q · filed 2026-08-04 | $1.64B derived: sum of 3 quarters · filed 2026-08-04 | $2.16B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $634.50M 10-Q · filed 2026-05-06 | $1.02B derived: sum of 2 quarters · filed 2026-05-06 | $1.53B derived: sum of 3 quarters · filed 2026-05-06 | $1.53B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $381.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $898.10M derived: sum of 2 quarters · filed 2026-02-25 | $898.10M derived: sum of 3 quarters · filed 2026-02-25 | $899.90M 10-K · filed 2026-02-25 |
| 2024-09-30 | $517.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $517.00M derived: sum of 2 quarters · filed 2025-11-05 | $518.80M 10-Q · filed 2025-11-05 | $519.50M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.80M 10-Q · filed 2025-08-06 | $2.50M derived: sum of 3 quarters · filed 2026-02-25 | $4.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $1.80M 10-Q · filed 2025-05-06 | $2.50M derived: sum of 2 quarters · filed 2026-02-25 | $4.10M derived: sum of 3 quarters · filed 2026-02-25 | $7.70M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.30M derived: sum of 2 quarters · filed 2026-02-25 | $5.90M derived: sum of 3 quarters · filed 2026-02-25 | $9.10M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $5.20M derived: sum of 2 quarters · filed 2024-11-06 | $8.40M 10-Q · filed 2024-11-06 | $21.40M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $6.80M 10-Q · filed 2024-07-31 | $19.80M derived: sum of 3 quarters · filed 2025-02-28 | $208.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $3.20M 10-Q · filed 2024-04-29 | $16.20M derived: sum of 2 quarters · filed 2025-02-28 | $204.70M derived: sum of 3 quarters · filed 2025-02-28 | $244.90M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $201.50M derived: sum of 2 quarters · filed 2025-02-28 | $241.70M derived: sum of 3 quarters · filed 2025-02-28 | $315.80M 10-K · filed 2025-02-28 |
| 2022-09-30 | $188.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-27 | $228.70M derived: sum of 2 quarters · filed 2023-10-27 | $302.80M 10-Q · filed 2023-10-27 | $1.21B derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-06-30 | $40.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $114.30M 10-Q · filed 2023-07-28 | $1.02B derived: sum of 3 quarters · filed 2024-02-12 | $1.37B derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-03-31 | $74.10M 10-Q · filed 2023-04-28 | $981.40M derived: sum of 2 quarters · filed 2024-02-12 | $1.33B derived: sum of 3 quarters · filed 2024-02-12 | $1.63B derived: sum of 4 quarters · filed 2024-02-12 |
| 2021-12-31 | $907.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-12 | $1.25B derived: sum of 2 quarters · filed 2024-02-12 | $1.55B derived: sum of 3 quarters · filed 2024-02-12 | $1.63B 10-K · filed 2024-02-12 |
| 2021-09-30 | $345.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $644.60M derived: sum of 2 quarters · filed 2022-10-28 | $722.00M 10-Q · filed 2022-10-28 | $1.02B derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-06-30 | $299.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $376.50M 10-Q · filed 2022-07-29 | $671.90M derived: sum of 3 quarters · filed 2023-02-13 | $790.50M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-03-31 | $77.40M 10-Q · filed 2022-04-28 | $372.80M derived: sum of 2 quarters · filed 2023-02-13 | $491.40M derived: sum of 3 quarters · filed 2023-02-13 | $616.20M derived: sum of 4 quarters · filed 2023-02-13 |
| 2020-12-31 | $295.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-13 | $414.00M derived: sum of 2 quarters · filed 2023-02-13 | $538.80M derived: sum of 3 quarters · filed 2023-02-13 | $689.70M 10-K · filed 2023-02-13 |
| 2020-09-30 | $118.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $243.40M derived: sum of 2 quarters · filed 2021-10-29 | $394.30M 10-Q · filed 2021-10-29 | $737.20M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-06-30 | $124.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $275.70M 10-Q · filed 2021-07-30 | $618.60M derived: sum of 3 quarters · filed 2022-02-14 | $638.20M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-03-31 | $150.90M 10-Q · filed 2021-04-28 | $493.80M derived: sum of 2 quarters · filed 2022-02-14 | $513.40M derived: sum of 3 quarters · filed 2022-02-14 | $588.80M derived: sum of 4 quarters · filed 2022-02-14 |
| 2019-12-31 | $342.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $362.50M derived: sum of 2 quarters · filed 2022-02-14 | $437.90M derived: sum of 3 quarters · filed 2022-02-14 | $437.90M 10-K · filed 2022-02-14 |
| 2019-09-30 | $19.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | $95.00M derived: sum of 2 quarters · filed 2020-10-26 | $95.00M 10-Q · filed 2020-10-26 | $229.00M derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-06-30 | $75.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | $75.40M 10-Q · filed 2020-07-27 | $209.40M derived: sum of 3 quarters · filed 2021-02-12 | $324.70M derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-03-31 | $0.00 10-Q · filed 2020-04-28 | $134.00M derived: sum of 2 quarters · filed 2021-02-12 | $249.30M derived: sum of 3 quarters · filed 2021-02-12 | |
| 2018-12-31 | $134.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $249.30M derived: sum of 2 quarters · filed 2021-02-12 | $249.30M 10-K · filed 2021-02-12 | |
| 2018-09-30 | $115.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-25 | $115.30M 10-Q · filed 2019-10-25 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-07-26 | |||
| 2017-12-31 | $52.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $197.50M derived: sum of 2 quarters · filed 2020-02-14 | $529.80M 10-K · filed 2020-02-14 | |
| 2017-09-30 | $145.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $477.80M 10-Q · filed 2018-10-26 | ||
| 2017-06-30 | $332.30M 10-Q · filed 2018-07-27 | |||
| 2016-12-31 | $470.40M 10-K · filed 2019-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |